GSK (NYSE:GSK) Shares Gap Down – Should You Sell?

GSK PLC Sponsored ADR (NYSE:GSK) gapped down prior to trading on Wednesday. The stock had previously closed at $50.94, but opened at $47.65. GSK shares last traded at $48.7640, with a volume of 5,235,829 shares trading hands.

Trending Headlines about GSK

Here are the key news stories impacting GSK this week:

• Positive Sentiment: Third-quarter results exceeded expectations. Adjusted earnings were reported at approximately $1.45–$1.47 per share, ahead of consensus estimates near $1.33–$1.40, while revenue of roughly $11.8 billion also topped forecasts. GSK maintained its full-year targets. GSK beats third-quarter profit estimates, keeps annual targets
• Positive Sentiment: Specialty medicines continued to grow. HIV, oncology and respiratory products delivered strong or double-digit growth, offsetting weakness in vaccines and broadly flat general-medicine sales. The performance supports management’s strategy of emphasizing higher-growth specialty drugs. GSK Sales Get Boost From Specialty Medicines
• Positive Sentiment: Pipeline activity could improve future growth. GSK expects to expand its cancer-drug trial portfolio significantly next year following recent dealmaking, while its newly approved Hibsago hepatitis B vaccine is preparing for a focused U.S. launch. GSK Sees Cancer-Drug Pipeline Nearly Doubling Next Year After Dealmaking Spree
• Neutral Sentiment: Management also highlighted efforts to improve transparency around clinical-trial results, potentially helping investor confidence over time, although the near-term financial impact is unclear. GSK vows transparency push
• Negative Sentiment: Vaccine sales missed expectations and declined amid weaker adult demand. This was the primary reason the earnings beat failed to satisfy investors, particularly as vaccines remain an important part of GSK’s portfolio. GSK shares slide after weaker vaccine sales
• Negative Sentiment: Investors are also concerned about mounting costs and doubts over the pipeline’s ability to replace slowing vaccine revenue, increasing pressure on management to demonstrate sustained growth. GSK shares dive as weaker sales and mounting costs unnerve investors

Analyst Ratings Changes

A number of research analysts have commented on GSK shares. Royal Bank Of Canada began coverage on shares of GSK in a research note on Tuesday, September 8th. They set a “sector perform” rating for the company. JPMorgan Chase & Co. reiterated a “sell” rating on shares of GSK in a research note on Thursday, October 1st. Weiss Ratings reissued a “hold (c+)” rating on shares of GSK in a report on Tuesday. Berenberg Bank restated a “buy” rating on shares of GSK in a research report on Tuesday, October 6th. Finally, Barclays reaffirmed a “sell” rating on shares of GSK in a research note on Monday, September 7th. Four research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $55.33.

GSK Stock Down 4.3%

The company has a current ratio of 0.82, a quick ratio of 0.52 and a debt-to-equity ratio of 0.81. The company has a market cap of $98.66 billion, a P/E ratio of 15.27, a price-to-earnings-growth ratio of 2.28 and a beta of 0.33. The firm’s 50 day moving average price is $49.62 and its 200-day moving average price is $52.36.

GSK (NYSE:GSK) last issued its quarterly earnings data on Tuesday, July 28th. The pharmaceutical company reported $1.36 EPS for the quarter, topping the consensus estimate of $1.27 by $0.09. GSK had a return on equity of 43.23% and a net margin of 14.56%. The business had revenue of $11.14 billion for the quarter, compared to the consensus estimate of $11.02 billion. During the same quarter last year, the business posted $0.47 EPS. The firm’s revenue was up 5.3% compared to the same quarter last year. As a group, equities research analysts expect that GSK PLC Sponsored ADR will post 4.78 EPS for the current year.

Institutional Trading of GSK

Hedge funds and other institutional investors have recently modified their holdings of the stock. NewEdge Advisors LLC increased its stake in shares of GSK by 842.9% in the 2nd quarter. NewEdge Advisors LLC now owns 953,574 shares of the pharmaceutical company’s stock valued at $49,986,000 after acquiring an additional 852,437 shares in the last quarter. Waverly Advisors LLC increased its position in GSK by 1,372.8% in the second quarter. Waverly Advisors LLC now owns 290,593 shares of the pharmaceutical company’s stock worth $15,233,000 after buying an additional 270,863 shares during the last quarter. Keystone Financial Planning Inc. lifted its position in shares of GSK by 3,114.8% during the second quarter. Keystone Financial Planning Inc. now owns 195,590 shares of the pharmaceutical company’s stock worth $10,253,000 after acquiring an additional 189,506 shares in the last quarter. Kahn Brothers Group Inc. purchased a new position in GSK during the second quarter valued at approximately $8,305,000. Finally, Mondrian Investment Partners LTD grew its position in GSK by 1.1% during the third quarter. Mondrian Investment Partners LTD now owns 4,965,946 shares of the pharmaceutical company’s stock worth $239,210,000 after buying an additional 55,116 shares in the last quarter. Institutional investors own 15.74% of the company’s stock.

GSK Company Profile

GSK plc, formerly GlaxoSmithKline, is a global biopharmaceutical company headquartered in Brentford, England. The company focuses on researching, developing and commercializing medicines and vaccines designed to prevent and treat infectious diseases, respiratory conditions, immune-related disorders and certain cancers.

Its vaccine portfolio includes products such as Shingrix for shingles, Arexvy for respiratory syncytial virus (RSV) in older adults, and vaccines targeting meningitis, influenza and other infectious diseases.